290 related articles for article (PubMed ID: 37344261)
21. Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system.
Chen C; Fu F; Ding L; Fang J; Xiao J
Front Immunol; 2022; 13():938322. PubMed ID: 36172346
[TBL] [Abstract][Full Text] [Related]
22. Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
Klein NP; Lewis N; Goddard K; Fireman B; Zerbo O; Hanson KE; Donahue JG; Kharbanda EO; Naleway A; Nelson JC; Xu S; Yih WK; Glanz JM; Williams JTB; Hambidge SJ; Lewin BJ; Shimabukuro TT; DeStefano F; Weintraub ES
JAMA; 2021 Oct; 326(14):1390-1399. PubMed ID: 34477808
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents.
Karlstad Ø; Hovi P; Husby A; Härkänen T; Selmer RM; Pihlström N; Hansen JV; Nohynek H; Gunnes N; Sundström A; Wohlfahrt J; Nieminen TA; Grünewald M; Gulseth HL; Hviid A; Ljung R
JAMA Cardiol; 2022 Jun; 7(6):600-612. PubMed ID: 35442390
[TBL] [Abstract][Full Text] [Related]
24. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
25. Incidence Rates and Clinical Characteristics of Patients With Confirmed Myocarditis or Pericarditis Following COVID-19 mRNA Vaccination: Experience of the Veterans Health Administration Through 9 October 2022.
Luo J; Hur K; Salone C; Huang N; Burk M; Pandey L; Thakkar B; Donahue M; Cunningham F
Open Forum Infect Dis; 2023 Jul; 10(7):ofad268. PubMed ID: 37469619
[TBL] [Abstract][Full Text] [Related]
26. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J
Nat Med; 2022 Feb; 28(2):410-422. PubMed ID: 34907393
[TBL] [Abstract][Full Text] [Related]
27. Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.
Nasreen S; Calzavara A; Buchan SA; Thampi N; Johnson C; Wilson SE; Kwong JC;
Vaccine; 2022 May; 40(24):3305-3312. PubMed ID: 35527057
[TBL] [Abstract][Full Text] [Related]
28. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination.
Goddard K; Lewis N; Fireman B; Weintraub E; Shimabukuro T; Zerbo O; Boyce TG; Oster ME; Hanson KE; Donahue JG; Ross P; Naleway A; Nelson JC; Lewin B; Glanz JM; Williams JTB; Kharbanda EO; Katherine Yih W; Klein NP
Vaccine; 2022 Aug; 40(35):5153-5159. PubMed ID: 35902278
[TBL] [Abstract][Full Text] [Related]
29. Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines.
Naveed Z; Li J; Wilton J; Spencer M; Naus M; Velásquez García HA; Kwong JC; Rose C; Otterstatter M; Janjua NZ;
J Am Coll Cardiol; 2022 Nov; 80(20):1900-1908. PubMed ID: 36357091
[TBL] [Abstract][Full Text] [Related]
30. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022.
Rosenblum HG; Wallace M; Godfrey M; Roper LE; Hall E; Fleming-Dutra KE; Link-Gelles R; Pilishvili T; Williams J; Moulia DL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley MF; Meyer S; Oliver SE; Twentyman E
MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(45):1436-1441. PubMed ID: 36355612
[TBL] [Abstract][Full Text] [Related]
31. Booster vaccination with SARS-CoV-2 mRNA vaccines and myocarditis in adolescents and young adults: a Nordic cohort study.
Hviid A; Nieminen TA; Pihlström N; Gunnes N; Dahl J; Karlstad Ø; Gulseth HL; Sundström A; Husby A; Hansen JV; Ljung R; Hovi P
Eur Heart J; 2024 Apr; 45(15):1327-1335. PubMed ID: 38365960
[TBL] [Abstract][Full Text] [Related]
32. Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform.
Walker JL; Schultze A; Tazare J; Tamborska A; Singh B; Donegan K; Stowe J; Morton CE; Hulme WJ; Curtis HJ; Williamson EJ; Mehrkar A; Eggo RM; Rentsch CT; Mathur R; Bacon S; Walker AJ; Davy S; Evans D; Inglesby P; Hickman G; MacKenna B; Tomlinson L; Ca Green A; Fisher L; Cockburn J; Parry J; Hester F; Harper S; Bates C; Evans SJ; Solomon T; Andrews NJ; Douglas IJ; Goldacre B; Smeeth L; McDonald HI
Vaccine; 2022 Jul; 40(32):4479-4487. PubMed ID: 35715350
[TBL] [Abstract][Full Text] [Related]
33. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
Faksova K; Walsh D; Jiang Y; Griffin J; Phillips A; Gentile A; Kwong JC; Macartney K; Naus M; Grange Z; Escolano S; Sepulveda G; Shetty A; Pillsbury A; Sullivan C; Naveed Z; Janjua NZ; Giglio N; Perälä J; Nasreen S; Gidding H; Hovi P; Vo T; Cui F; Deng L; Cullen L; Artama M; Lu H; Clothier HJ; Batty K; Paynter J; Petousis-Harris H; Buttery J; Black S; Hviid A
Vaccine; 2024 Apr; 42(9):2200-2211. PubMed ID: 38350768
[TBL] [Abstract][Full Text] [Related]
34. Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA Vaccination-A nationwide study.
Su WJ; Liu YL; Chang CH; Lin YC; Huang WI; Wu LC; Chen SF; Lin YS; Hsieh YL; Yang CA; Lin CH; Chan KA; Lee PI; Chuang JH; Yang CH
J Microbiol Immunol Infect; 2023 Jun; 56(3):558-565. PubMed ID: 36804307
[TBL] [Abstract][Full Text] [Related]
35. Exacerbation of immune thrombocytopenia following initial and booster vaccination with Pfizer-BioNTech COVID-19 vaccine.
Aharoni M; Leader A; Shochat T; Raanani P; Spectre G
Platelets; 2022 Jul; 33(5):781-786. PubMed ID: 35536172
[TBL] [Abstract][Full Text] [Related]
36. Racial and ethnic disparities in COVID-19 booster vaccination among U.S. older adults differ by geographic region and Medicare enrollment.
Hayes KN; Harris DA; Zullo AR; Chachlani P; Wen KJ; Smith-Ray RL; Djibo DA; McCarthy EP; Pralea A; Singh TG; McMahill-Walraven C; Taitel MS; Deng Y; Gravenstein S; Mor V
Front Public Health; 2023; 11():1243958. PubMed ID: 37637796
[TBL] [Abstract][Full Text] [Related]
37. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Blanc PG; Gwira Baumblatt JA; Woo EJ; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):249-254. PubMed ID: 35176008
[TBL] [Abstract][Full Text] [Related]
38. Adverse Events Following COVID-19 Vaccination in Adolescents: Insights From Pharmacovigilance Study of VigiBase.
Kim DH; Kim JH; Oh IS; Choe YJ; Choe SA; Shin JY
J Korean Med Sci; 2024 Mar; 39(8):e76. PubMed ID: 38442719
[TBL] [Abstract][Full Text] [Related]
39. A population-based assessment of myocarditis after messenger RNA COVID-19 booster vaccination among adult recipients.
Naveed Z; Li J; Naus M; Velásquez García HA; Wilton J; Janjua NZ;
Int J Infect Dis; 2023 Jun; 131():75-78. PubMed ID: 36967038
[TBL] [Abstract][Full Text] [Related]
40. Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series.
Fazlollahi A; Zahmatyar M; Noori M; Nejadghaderi SA; Sullman MJM; Shekarriz-Foumani R; Kolahi AA; Singh K; Safiri S
Rev Med Virol; 2022 Jul; 32(4):e2318. PubMed ID: 34921468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
